TWT-11796-64746
4 vaccinations
6 coded responses
46 check-ins
6 free-text entries
0 call cases
- Sex
- Female
- Age at first dose
- 41-45
- ZIP prefix
- 207 / MD
- Registered
- 2021-12-22
- Relationship
- Self
- Race
- Black or African American
- Ethnicity
- Hispanic or Latino
Timeline
-
2021-12-22
Registered in v-safe
-
2021-12-22
Dose 1 — Pfizer-BioNTech
- 2021-12-22
-
2021-12-23
Health check-in — days 1–6 daily, dose 1Feeling: Good · Site: Pain · Headache, Fatigue or tirednessAdult check-in
- 2021-12-24
- 2021-12-25
- 2021-12-26
- 2021-12-27
- 2021-12-28
- 2021-12-29
- 2022-01-05
- 2022-01-12
-
2022-01-14
Dose 2 — Pfizer-BioNTech
- 2022-01-14
-
2022-01-15
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Site: Pain · Fatigue or tirednessAdult check-in
- 2022-01-16
- 2022-01-17
- 2022-01-18
- 2022-01-19
- 2022-01-20
- 2022-01-21
- 2022-01-30
- 2022-02-04
- 2022-02-11
- 2022-02-18
- 2022-02-25
- 2022-04-15
-
2022-07-02
Dose 3 — Pfizer-BioNTech
- 2022-07-02
- 2022-07-03
- 2022-07-04
-
2022-07-05
Survey response — days 1–6 daily, dose 3MedDRA: Nasopharyngitis — Feeling: Fair · Fatigue or tirednessFree text: Cold symptomsMedDRA releases: 2024-11 · check-in free text available
-
2022-07-06
Survey response — days 1–6 daily, dose 3MedDRA: Nasopharyngitis, Respiratory tract congestion — Feeling: FairFree text: Cold symptoms - congestionMedDRA releases: 2024-11 · check-in free text available
-
2022-07-08
Survey response — days 1–6 daily, dose 3MedDRA: Nasal congestion — Feeling: GoodFree text: Nasal congestionMedDRA releases: 2024-11 · check-in free text available
-
2022-07-09
Survey response — day 7, dose 3MedDRA: Nasal congestion — Feeling: GoodFree text: Nasal congestionMedDRA releases: 2024-11 · check-in free text available
- 2022-07-17
- 2022-07-23
-
2022-07-30
Survey response — day 28, dose 3MedDRA: Nasal congestion, Nasopharyngitis, Oropharyngeal pain, Rhinorrhoea — Feeling: FairFree text: Cold symptoms. Sore throat, nasal congestion, runny nose.MedDRA releases: 2024-11 · check-in free text available
- 2022-08-06
- 2022-08-13
-
2022-10-01
Survey response — 3 months, dose 3MedDRA: Nasopharyngitis — Feeling: GoodFree text: ColdMedDRA releases: 2024-11 · check-in free text available
- 2022-12-31
-
2023-01-03
Dose 4 — Pfizer-BioNTech
- 2023-01-06
- 2023-01-07
- 2023-01-08
- 2023-01-09
- 2023-01-24
- 2023-01-31
- 2023-02-07
- 2023-02-16
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-12-22 | Pfizer-BioNTech | No |
| 2 | 2022-01-14 | Pfizer-BioNTech | No |
| 3 | 2022-07-02 | Pfizer-BioNTech | No |
| 4 | 2023-01-03 | Pfizer-BioNTech | No |
Free text
Release 12 — days 1–6 daily, dose 3
Systemic reaction (other): Cold symptoms
Systemic reaction (other): Cold symptoms - congestion
Systemic reaction (other): Nasal congestion
Release 12 — day 7, dose 3
Systemic reaction (other): Nasal congestion
Release 12 — day 28, dose 3
Symptoms: Cold symptoms. Sore throat, nasal congestion, runny nose.
Release 12 — 3 months, dose 3
Symptoms: Cold
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Nasal congestion | · | · | ✓ |
| SD | Nasopharyngitis | · | · | ✓ |
| SD | Oropharyngeal pain | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
| SRO | Nasal congestion | · | · | ✓ |
| SRO | Nasopharyngitis | · | · | ✓ |
| SRO | Respiratory tract congestion | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release